Lilly: Alimta improves lung-cancer survival time

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.

Alimta is used as
a "maintenance therapy" for patients whose disease has not progressed after chemotherapy. In a study involving 663
patients, Lilly said patients treated with Alimta and best available care lived for an average of 13.4 months. Those treated
with best care and a placebo lived for an average of 10.6 months.

The company said patients with non-squamous tumors,
or the kind that Alimta is approved to treat, lived for 15.5 months, compared to 10.3 months for patients in the placebo group.
Non-squamous tumors make up about 70 percent of all lung cancers. Patients who had squamous tumors lived an average of 9.9
months if they were treated with Alimta, and 10.8 months if they were not.

Results of the study were published
in The Lancet, a British medical journal.

Alimta is an injection that is approved as a primary treatment for advanced
non-small cell lung cancer, in combination with chemotherapy, or on its own as a secondary treatment for the disease. It is
also approved as a treatment for mesothelioma.
 

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In